Running an infusion center is about more than just administering treatments—it’s about creating a network of trust with patients who rely on these therapies to manage their health conditions. One of the most effective ways to reach potential patients and grow your business is by connecting with them directly.
Running an infusion center is about more than just administering treatments—it’s about creating a network of trust with patients who rely on these therapies to manage their health conditions. One of the most effective ways to reach potential patients and grow your business is by connecting with them directly.
Entering the infusion therapy market presents both exciting opportunities and formidable challenges. From high upfront drug costs to complex reimbursement rules, new entrants must strike a careful balance to achieve profitability and maintain patient satisfaction.
Infusion providers should know the U.S. Department of Health and Human Services (HHS) published through its Office for Civil Rights (OCR) a new proposed rule to modify the Health Insurance Portability and Accountability Act of 1996 (HIPAA) Security Rule (Proposed Rule) for the first time since 2013 (the original rule was published in 2003).
By: Patrick LaVoie, CEO and Founder of Thrivory, Inc. Navigating Financial Options to Improve Your Infusion Center’s Performance Infusion centers play a vital role in the […]
Infusion providers focused on providing excellent patient care often ask themselves, “How do I design a clinical training program that focuses on clinician competency and excellent patient care?”
By: Tiffani Bouchard, CCS Managing JW and JZ Modifiers When Billing Single-Dose Drugs Managing JW and JZ modifiers when billing single-dose drugs can be challenging. As […]
By: Pamela McIntyre, CRNI, IgCN, OCN, and VA-BC Maximizing Efficiency in Ambulatory Infusion Centers When it comes to maximizing efficiency in ambulatory infusion centers, one of […]
By: Michael Rigas, Pharm.D., FNHIA Biosimilars are also known as follow-on biologics or subsequent-entry biologics. They are FDA-approved copies of the original “innovator” drug product that […]